139 related articles for article (PubMed ID: 38899431)
21. Real-World experience with efgartigimod in patients with myasthenia gravis.
Fuchs L; Shelly S; Vigiser I; Kolb H; Regev K; Schwartzmann Y; Vaknin-Dembinsky A; Dori A; Karni A
J Neurol; 2024 Jun; 271(6):3462-3470. PubMed ID: 38528163
[TBL] [Abstract][Full Text] [Related]
22. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
Katyal N; Narula N; Govindarajan R
J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study.
Narayanaswami P; Sanders DB; Thomas L; Thibault D; Blevins J; Desai R; Krueger A; Bibeau K; Liu B; Guptill JT;
Lancet Neurol; 2024 Mar; 23(3):267-276. PubMed ID: 38365379
[TBL] [Abstract][Full Text] [Related]
24. Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use.
Heo YA
CNS Drugs; 2023 May; 37(5):467-473. PubMed ID: 37000339
[TBL] [Abstract][Full Text] [Related]
25. Translation and validation of the arabic version of the revised 15-item myasthenia gravis quality-of-life questionnaire.
Alanazy MH; Abuzinadah AR; Muayqil T
Muscle Nerve; 2018 Apr; 57(4):581-585. PubMed ID: 28857210
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis.
Saccà F; Pane C; Espinosa PE; Sormani MP; Signori A
Eur J Neurol; 2023 Dec; 30(12):3854-3867. PubMed ID: 37204031
[TBL] [Abstract][Full Text] [Related]
27. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.
Howard JF; Karam C; Yountz M; O'Brien FL; Mozaffar T;
Ann Clin Transl Neurol; 2021 Jul; 8(7):1398-1407. PubMed ID: 34043280
[TBL] [Abstract][Full Text] [Related]
28. Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis.
Guptill JT; Sleasman JW; Steeland S; Sips M; Gelinas D; de Haard H; Azar A; Winthrop KL
Autoimmunity; 2022 Dec; 55(8):620-631. PubMed ID: 36036539
[TBL] [Abstract][Full Text] [Related]
29. Disease Severity Assessment and Short-Term Outcome in Patients with Myasthenia Gravis.
Vemuri D; Garuda BR; Gopi S; Kumar TS; Kumari UA
Ann Indian Acad Neurol; 2020; 23(2):215-219. PubMed ID: 32189865
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of outcome measures for myasthenia gravis subgroups.
Luo Y; Dong X; Peng Y; Cui B; Yan C; Jin W; Li Y; Zhou R; Huang K; Yang H
J Clin Neurosci; 2021 Sep; 91():270-275. PubMed ID: 34373039
[TBL] [Abstract][Full Text] [Related]
31. Association Between Myasthenia Gravis-Activities of Daily Living (MG-ADL) and EQ-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities.
Dewilde S; Qi CZ; Phillips G; Iannazzo S; Janssen MF
Adv Ther; 2023 Apr; 40(4):1818-1829. PubMed ID: 36867327
[TBL] [Abstract][Full Text] [Related]
32. Efgartigimod: First Approval.
Heo YA
Drugs; 2022 Feb; 82(3):341-348. PubMed ID: 35179720
[TBL] [Abstract][Full Text] [Related]
33. Real-World Case Series of Efgartigimod for Japanese Generalized Myasthenia Gravis: Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom Control.
Konno S; Uchi T; Kihara H; Sugimoto H
Biomedicines; 2024 May; 12(6):. PubMed ID: 38927421
[TBL] [Abstract][Full Text] [Related]
34. Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective.
Suzuki S; Uzawa A; Murai H
Expert Rev Clin Immunol; 2022 Dec; 18(12):1207-1215. PubMed ID: 36227228
[TBL] [Abstract][Full Text] [Related]
35. Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
Brandsema JF; Ginsberg M; Hoshino H; Mimaki M; Nagata S; Rao VK; Ruzhansky K; Suresh N; Tiongson E; Yamanouchi H; Frick G; Hicks E; Liao S; Howard JF;
Pediatr Neurol; 2024 Jul; 156():198-207. PubMed ID: 38810600
[TBL] [Abstract][Full Text] [Related]
36. Promising efficacy of Low-Dose rituximab in Muscle specific kinase antibody positive Myasthenia Gravis.
Yang X; Zhang W; Chang X; Li Z; Du R; Guo J
Neurosci Lett; 2024 Jan; 818():137561. PubMed ID: 37984485
[TBL] [Abstract][Full Text] [Related]
37. Efgartigimod as a novel FcRn inhibitor for autoimmune disease.
Yang Y; Shen Z; Shi F; Wang F; Wen N
Neurol Sci; 2024 Apr; ():. PubMed ID: 38644454
[TBL] [Abstract][Full Text] [Related]
38. Clinical experience with maintenance therapeutic plasma exchange in refractory generalized myasthenia gravis.
Sheckley H; Malhotra K; Katyal N; Narula N; Govindarajan R
J Clin Apher; 2021 Oct; 36(5):727-736. PubMed ID: 34241920
[TBL] [Abstract][Full Text] [Related]
39. Clinical Profile and Quality of Life in Myasthenia Gravis Using MGQOL15 R(Hindi): An Indian Perspective.
Majigoudra G; Duggal AK; Chowdhury D; Koul A; Todi VK; Roshan S
Ann Indian Acad Neurol; 2023; 26(4):441-446. PubMed ID: 37970285
[TBL] [Abstract][Full Text] [Related]
40. Efgartigimod is a new option for the treatment of thymoma associated myasthenia gravis: A case report.
Wang S; Wang Q; Jin L; Dong J; Ding J
Int J Surg Case Rep; 2024 Feb; 115():109241. PubMed ID: 38219512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
